Under Amgen and Servier’s cardiovascular collaboration, Servier has exercised its option to commercialize omecamtiv mecarbil in chronic heart failure in Europe, and the Commonwealth of Independent States, including Russia. Also, the companies omecamtiv mecarbil Phase III development program will move forward in collaboration with Cytokinetics. Servier will make a $10 million option exercise payment, as well as future milestone and royalty payments to Amgen. Servier will assume a share of the ...